Free Trial

Promis Neurosciences (PMN) 10K Form and Latest SEC Filings 2026

Promis Neurosciences logo
$10.99 -0.08 (-0.72%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Promis Neurosciences SEC Filings & Recent Activity

Promis Neurosciences (NASDAQ:PMN) has submitted 212+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on April 23, 2026.

Form 4
ProMIS Neurosciences Inc. Reports Ownership Change on Apr. 23, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Promis Neurosciences Files Current Report on Mar. 25, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Promis Neurosciences Files Annual Report on Mar. 25, 2026

The 10-K contains Promis Neurosciences's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Promis Neurosciences SEC Filing History

Browse Promis Neurosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/23/2026 8:25 PM
Kirwin Patrick D. (1927062) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2026 3:01 PM
Promis Neurosciences (1374339) Filer
Form DEF 14A
04/09/2026 3:02 PM
Promis Neurosciences (1374339) Filer
Form DEFA14A
04/09/2026 3:03 PM
Promis Neurosciences (1374339) Filer
Form ARS
04/07/2026 3:27 PM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Promis Neurosciences (1374339) Subject
Form SCHEDULE 13G
04/02/2026 11:15 PM
Promis Neurosciences (1374339) Filer
Form EFFECT
03/26/2026 11:15 PM
Promis Neurosciences (1374339) Filer
Form EFFECT
03/25/2026 4:22 PM
Promis Neurosciences (1374339) Filer
Form S-3
Registration statement under Securities Act of 1933  
03/25/2026 3:34 PM
Promis Neurosciences (1374339) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/25/2026 7:06 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/18/2026 11:26 AM
Promis Neurosciences (1374339) Subject
Wellington Biomedical Innovation Master Investors (0) Cayman
Form SCHEDULE 13G
03/06/2026 6:28 AM
Promis Neurosciences (1374339) Issuer
Williams Eugene (1927626) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 5:08 PM
Promis Neurosciences (1374339) Issuer
Williams Eugene (1927626) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2026 6:30 PM
ABG Global Life Science Capital Partners V GP Ltd (2080887) Reporting
ABG Global Life Science Capital Partners V GP, L.P. (2080886) Reporting
ABG V-SIV IX Ltd (2113290) Reporting
ABG V-SIV X Ltd (2113291) Reporting
Ally Bridge Group Global Life Science Capital Partners V, L.P. (1951727) Reporting
Promis Neurosciences (1374339) Issuer
Form 3
Initial statement of beneficial ownership of securities  
02/23/2026 7:31 AM
Kaplan Johanne (1967717) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 8:36 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Promis Neurosciences (1374339) Subject
Form SCHEDULE 13G/A
02/05/2026 7:39 PM
Promis Neurosciences (1374339) Issuer
Warma Neil K (1437911) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 7:40 PM
Kaplan Johanne (1967717) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 7:41 PM
Cashman Neil (1927064) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 7:36 PM
Kirwin Patrick D. (1927062) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 7:37 PM
Milbury Max A. (1927056) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 6:00 PM
ABG Management Ltd. (1832106) Reporting
Alex Slanix Paul (2092283) Reporting
Ally Bridge Group (0) NY
Ally Bridge MedAlpha Master Fund L.P. (1831963) Reporting
Promis Neurosciences (1374339) Issuer
Yu Fan (1668029) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 6:02 PM
ABG Management Ltd. (1832106) Filed by
Promis Neurosciences (1374339) Subject
Form SCHEDULE 13D/A
01/30/2026 7:25 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/16/2025 3:48 PM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/24/2025 7:30 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/19/2025 8:25 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 5:26 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Promis Neurosciences (1374339) Subject
Form SCHEDULE 13G/A
11/14/2025 1:12 PM
GREAT POINT PARTNERS LLC (1281446) Filed by
Promis Neurosciences (1374339) Subject
Form SCHEDULE 13G/A
11/12/2025 6:05 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2025 6:06 AM
Promis Neurosciences (1374339) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/29/2025 3:30 PM
ABG Management Ltd. (1832106) Filed by
Promis Neurosciences (1374339) Subject
Form SCHEDULE 13D
10/24/2025 3:30 PM
Alex Slanix Paul (2092283) Reporting
Promis Neurosciences (1374339) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/24/2025 3:34 PM
ABG Management Ltd. (1832106) Reporting
Alex Slanix Paul (2092283) Reporting
Ally Bridge Group (0) NY
Ally Bridge MedAlpha Master Fund L.P. (1831963) Reporting
Promis Neurosciences (1374339) Issuer
Yu Fan (1668029) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 3:10 PM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/23/2025 5:02 AM
Promis Neurosciences (1374339) Subject
SPHERA FUNDS MANAGEMENT LTD. (1496201) Filed by
Form SCHEDULE 13G/A
10/15/2025 4:24 PM
Promis Neurosciences (1374339) Subject
Sclar Jeremy M. (1955608) Filed by
Form SCHEDULE 13G/A
10/06/2025 8:12 AM
Milbury Max A. (1927056) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2025 3:15 PM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2025 3:15 PM
Jeremy M. Sclar 2012 Irrevocable Family Trust (2089163) Reporting
Promis Neurosciences (1374339) Issuer
Form 3
Initial statement of beneficial ownership of securities  
09/30/2025 3:17 PM
Jeremy M. Sclar 2012 Irrevocable Family Trust (2089163) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 7:58 AM
Promis Neurosciences (1374339) Issuer
Warma Neil K (1437911) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 7:45 AM
ALTSTIEL LARRY DOUGLAS (1619444) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 7:48 AM
Kaplan Johanne (1967717) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 7:51 AM
Cashman Neil (1927064) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 7:54 AM
Milbury Max A. (1927056) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2025 4:14 PM
Promis Neurosciences (1374339) Filer
Form PRE 14A
09/10/2025 11:15 PM
Promis Neurosciences (1374339) Filer
Form EFFECT
09/04/2025 3:30 PM
Promis Neurosciences (1374339) Filer
Form S-3
Registration statement under Securities Act of 1933  
09/03/2025 6:05 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/24/2025 11:15 PM
Promis Neurosciences (1374339) Filer
Form EFFECT
08/14/2025 3:15 PM
GORDON MICHAEL S (1034608) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2025 6:05 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2025 6:10 AM
Promis Neurosciences (1374339) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/04/2025 4:49 PM
ABG Management Ltd. (1832106) Reporting
Ally Bridge Group (0) NY
Ally Bridge MedAlpha Master Fund L.P. (1831963) Reporting
Promis Neurosciences (1374339) Issuer
Yu Fan (1668029) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/04/2025 4:55 PM
ABG Management Ltd. (1832106) Filed by
Promis Neurosciences (1374339) Subject
Form SCHEDULE 13G
07/31/2025 8:36 PM
Promis Neurosciences (1374339) Subject
Shaf QIC LLC (2038058) Filed by
Form SCHEDULE 13G/A
07/29/2025 7:18 PM
Promis Neurosciences (1374339) Issuer
Title 19 Promis (2005531) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2025 7:20 PM
GORDON MICHAEL S (1034608) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/28/2025 6:15 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/22/2025 5:30 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/16/2025 4:04 PM
Promis Neurosciences (1374339) Issuer
Shafmaster Madge K. (1927066) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2025 4:11 PM
Kirwin Patrick D. (1927062) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2025 4:23 PM
Mandel-Brehm Josh (1927058) Reporting
Promis Neurosciences (1374339) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2025 3:45 PM
Promis Neurosciences (1374339) Issuer
Williams Eugene (1927626) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 7:00 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/12/2025 6:37 AM
Promis Neurosciences (1374339) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/12/2025 6:39 AM
Promis Neurosciences (1374339) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Promis Neurosciences SEC Filings - Frequently Asked Questions

Promis Neurosciences (PMN) has submitted 212+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Promis Neurosciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 4 submitted on April 23, 2026. This was an insider ownership change filed by 4 - ProMIS Neurosciences Inc. (0001374339) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:PMN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners